Neurophysiological changes induced by the botulinum toxin type A injection in children with cerebral palsy.
In the last few years botulinum toxin type A (BTX-A) has been widely used in the management of spasticity in children with cerebral palsy in order to reduce hypertonicity and improve functional outcomes enhancing motor skill development. The botulinum toxin injection seems to interact with intrafusal and extrafusal fibers producing a reduction of hypertone both through synaptic blockade and inhibition of stretch reflex loop and these changes may influence not only the spinal cord but also the central nervous system (CNS). The purpose of our study was to determine the neurophysiological changes induced by the BTX-A through an evaluation of cortical somatosensory Evoked Potential (SEP) and Soleus H wave, that is the index of excitability of stretch reflex loop. Eighteen children with Cerebral Palsy (CP), aged between 5 and 12, were recruited at Children's Hospital "Bambino Gesù" of Rome. All children were evaluated with appropriate clinical scales before and 1 month after the BTX-A injection. Neurophysiological measurements were performed before, and 1 month after botulinum toxin injection through lower limb SEPs, M-wave and Soleus H wave recording. After the injection the results showed a statistically significant improvement both of clinical scales and the neurophysiological variables. These findings suggest that spasticity itself can be considered as a factor affecting the cortical SEPs. And even though it seems that BTX-A does not have any direct central effect on sensory pathways we suppose an indirect mechanism on modulation of afferent fibers Ia due to the modification induced by BTX-A to central loop reflex.
Frascarelli
Flaminia
F
Pediatric Neuro-Rehabilitation Division, Children's Hospital Bambino Gesù IRCCS, Via Torre di Palidoro, Passoscuro (Fiumicino), Rome 00050, Italy. flaminia.frascarelli@opbg.net
Di Rosa
Giuseppe
G
Bisozzi
Eleonora
E
Castelli
Enrico
E
Santilli
Valter
V
D019274:Botulinum Toxins, Type A / Q000008:administration & dosage* / Q000009:adverse effects; D002547:Cerebral Palsy / Q000188:drug therapy* / Q000503:physiopathology; D002648:Child; D002675:Child, Preschool; D005073:Evoked Potentials, Somatosensory / Q000187:drug effects / Q000502:physiology; D005260:Female; D006181:H-Reflex / Q000187:drug effects / Q000502:physiology; D006801:Humans; D008297:Male; D018485:Muscle Fibers, Skeletal / Q000187:drug effects / Q000502:physiology; D009128:Muscle Spasticity / Q000188:drug therapy / Q000503:physiopathology; D018482:Muscle, Skeletal / Q000187:drug effects / Q000503:physiopathology; D009433:Neural Inhibition / Q000187:drug effects / Q000502:physiology; D009465:Neuromuscular Agents / Q000008:administration & dosage* / Q000009:adverse effects; D012026:Reflex, Stretch / Q000187:drug effects / Q000502:physiology
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A